1004769-97-4

Upstream product

• 600-00-0 ethyl 2-bromoisobutyrate 
• 937-00-8 3-trifluoromethyl-thiophenol 

Downstream Products

• 1374864-82-0 2-methyl-2-((3-(trifluoromethyl)phenyl)sulfonyl)propanamide 
• 1276680-55-7 2-methyl-2-((3-(trifluoromethyl)phenyl)sulfonyl)propan-1-amine 
• 1374864-32-0 6-(2-methyl-2-((3-(trifluoromethyl)phenyl)sulfonyl)propyl)-2-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one 
• 1004770-17-5 2-methyl-2-(3-trifluoromethyl-benzenesulfonyl)-propionic acid ethyl ester 

Relevant academic research and scientific papers

BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

The invention relates to bisarylsulfone and dialkylarylsulfone compounds (e.g., compounds according to any of Formulas (I)-(IX) or compounds (1)-(227) of Tables 4 and 5) useful in treating conditions associated with calcium channel function, and particularly conditions associated with N-type calcium channel activity. The invention also relates to pharmaceutical compositions that include these bisarylsulfone compounds, as well methods for the treatment of conditions such as cardiovascular disease, epilepsy, cancer and pain.

COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu

Compounds Which Modulate The CB2 Receptor

Compound of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful